M201-A / AETAS Pharma - LARVOL DELTA

"Letter to the Editor: Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation". (PubMed, J Pharmacol Exp Ther) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular

Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation. (PubMed, J Pharmacol Exp Ther) - "It was the most active conversion metabolite when K201 was administered orally in patients with paroxysmal AF. These pharmacological effects of M201-A, combined with its inhibitory actions on RyR2, provide a promising therapeutic option for treating AF."

Journal • Atrial Fibrillation • Cardiovascular

A comprehensive study of novel extremophilic soil bacterial isolates from Sundarbans mangrove sediments as a biocontrol agent for mosquito vector management. (PubMed, Pest Manag Sci) - "Importantly, non-pathogenicity tests confirmed its safety for humans and supports its potential for sustainable mosquito vector management in saline environments. This study underscores viability of the H. marinus MB201 as an eco-friendly solution for mosquito control in the context of climate change."

Journal • Infectious Disease

In vivo cardiovascular profile of ryanodine receptor 2 inhibitor M201-A: Utility as an anti-atrial fibrillatory drug for patients suffering from heart failure with preserved ejection fraction. (PubMed, J Pharmacol Sci) - "M201-A prolonged J-Tpeakc without prolonging Tpeak-Tend or terminal repolarization period, indicating the risk of causing torsade de pointes is negligible. Thus, M201-A is expected to become a hopeful therapeutic strategy for patients having pathology of both AF and HFpEF."

Journal • Preclinical • Anesthesia • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study. (PubMed, Br J Pharmacol) - "The novel drug M201-A inhibited diastolic Ca2+ leak via RyR2, improved cardiac lusi-inotropic effects in rats, and enhanced natriuresis and renal function in humans. These findings suggest that this drug may offer a potential new treatment option for chronic kidney disease and heart failure."

Journal • P1 data • Preclinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Yuji KUMAGAI; Recruiting ➔ Completed

Clinical • Trial completion

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Kitasato University; Recruiting ➔ Completed

Clinical • Trial completion

Phylogenetic history of patrilineages rare in northern and eastern Europe from large-scale re-sequencing of human Y-chromosomes. (PubMed, Eur J Hum Genet) - "We construct dated phylogenies for haplogroups E2-M215, J2-M172, G-M201 and Q-M242 on the basis of 421 (of them 282 novel) high-coverage chrY sequences collected from large-scale databases focusing on populations of NEE. We assess the possible direction of influx of ancestral carriers for some of these male lineages. In addition, we demonstrate the congruency of paternal haplogroup composition of our dataset with two independent population-based cohorts from Estonia and Sweden."

Journal

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation (clinicaltrials.gov) - P2; N=42; Recruiting; Sponsor: Kitasato University

Clinical • New P2 trial • Atrial Fibrillation • Cardiovascular

A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease. (PubMed, Neurobiol Aging) - "Amelioration of motor deficits and dopamine neuron loss by MP201 treatment was associated with reductions in microglial and astrocyte activation and neuroinflammation. These preclinical findings suggest the potential application of mitochondrial uncoupling agents such as MP201 as disease-modifying therapies for PD."

Journal • Preclinical • CNS Disorders • Immunology • Movement Disorders • Parkinson's Disease